![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: A2ML1 |
Gene summary for A2ML1 |
![]() |
Gene information | Species | Human | Gene symbol | A2ML1 | Gene ID | 144568 |
Gene name | alpha-2-macroglobulin like 1 | |
Gene Alias | CPAMD9 | |
Cytomap | 12p13.31 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | A8K2U0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
144568 | A2ML1 | CCI_1 | Human | Cervix | CC | 2.49e-04 | 7.68e-01 | 0.528 |
144568 | A2ML1 | CCI_3 | Human | Cervix | CC | 1.67e-04 | 7.48e-01 | 0.516 |
144568 | A2ML1 | H2 | Human | Cervix | HSIL_HPV | 3.46e-13 | 4.20e-01 | 0.0632 |
144568 | A2ML1 | LZE22T | Human | Esophagus | ESCC | 1.57e-02 | 2.74e-01 | 0.068 |
144568 | A2ML1 | P1T-E | Human | Esophagus | ESCC | 1.64e-05 | 3.42e-01 | 0.0875 |
144568 | A2ML1 | P23T-E | Human | Esophagus | ESCC | 6.05e-08 | 2.64e-01 | 0.108 |
144568 | A2ML1 | P31T-E | Human | Esophagus | ESCC | 8.13e-04 | 1.17e-01 | 0.1251 |
144568 | A2ML1 | P82T-E | Human | Esophagus | ESCC | 2.06e-06 | 6.58e-01 | 0.1072 |
144568 | A2ML1 | P84T-E | Human | Esophagus | ESCC | 2.04e-06 | 1.18e+00 | 0.0933 |
144568 | A2ML1 | P127T-E | Human | Esophagus | ESCC | 1.56e-02 | 1.10e-01 | 0.0826 |
144568 | A2ML1 | P130T-E | Human | Esophagus | ESCC | 1.35e-23 | 4.44e-01 | 0.1676 |
144568 | A2ML1 | C38 | Human | Oral cavity | OSCC | 3.16e-16 | 1.12e+00 | 0.172 |
144568 | A2ML1 | C43 | Human | Oral cavity | OSCC | 1.87e-31 | 9.03e-01 | 0.1704 |
144568 | A2ML1 | C57 | Human | Oral cavity | OSCC | 1.60e-47 | 1.59e+00 | 0.1679 |
144568 | A2ML1 | LN38 | Human | Oral cavity | OSCC | 6.23e-08 | 1.07e+00 | 0.168 |
144568 | A2ML1 | SYSMH3 | Human | Oral cavity | OSCC | 1.93e-04 | 1.93e-01 | 0.2442 |
144568 | A2ML1 | SYSMH4 | Human | Oral cavity | OSCC | 1.04e-02 | 8.85e-02 | 0.1226 |
144568 | A2ML1 | SYSMH5 | Human | Oral cavity | OSCC | 8.18e-06 | 1.48e-01 | 0.0647 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005254710 | Cervix | CC | regulation of peptidase activity | 112/2311 | 461/18723 | 6.70e-13 | 3.08e-10 | 112 |
GO:005254810 | Cervix | CC | regulation of endopeptidase activity | 103/2311 | 432/18723 | 1.89e-11 | 5.14e-09 | 103 |
GO:004586110 | Cervix | CC | negative regulation of proteolysis | 80/2311 | 351/18723 | 2.88e-08 | 1.98e-06 | 80 |
GO:00513469 | Cervix | CC | negative regulation of hydrolase activity | 81/2311 | 379/18723 | 4.27e-07 | 1.67e-05 | 81 |
GO:00104669 | Cervix | CC | negative regulation of peptidase activity | 60/2311 | 262/18723 | 1.27e-06 | 4.34e-05 | 60 |
GO:001095110 | Cervix | CC | negative regulation of endopeptidase activity | 56/2311 | 252/18723 | 7.43e-06 | 1.74e-04 | 56 |
GO:005254715 | Cervix | HSIL_HPV | regulation of peptidase activity | 52/737 | 461/18723 | 8.35e-12 | 6.81e-09 | 52 |
GO:005254815 | Cervix | HSIL_HPV | regulation of endopeptidase activity | 48/737 | 432/18723 | 9.20e-11 | 3.70e-08 | 48 |
GO:004586115 | Cervix | HSIL_HPV | negative regulation of proteolysis | 36/737 | 351/18723 | 1.64e-07 | 1.02e-05 | 36 |
GO:001046614 | Cervix | HSIL_HPV | negative regulation of peptidase activity | 30/737 | 262/18723 | 1.66e-07 | 1.03e-05 | 30 |
GO:001095113 | Cervix | HSIL_HPV | negative regulation of endopeptidase activity | 29/737 | 252/18723 | 2.39e-07 | 1.44e-05 | 29 |
GO:005134614 | Cervix | HSIL_HPV | negative regulation of hydrolase activity | 37/737 | 379/18723 | 3.81e-07 | 2.06e-05 | 37 |
GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
GO:0052548111 | Esophagus | ESCC | regulation of endopeptidase activity | 253/8552 | 432/18723 | 3.68e-08 | 6.78e-07 | 253 |
GO:0045861111 | Esophagus | ESCC | negative regulation of proteolysis | 195/8552 | 351/18723 | 1.13e-04 | 7.85e-04 | 195 |
GO:0051346110 | Esophagus | ESCC | negative regulation of hydrolase activity | 208/8552 | 379/18723 | 1.76e-04 | 1.14e-03 | 208 |
GO:001046620 | Esophagus | ESCC | negative regulation of peptidase activity | 140/8552 | 262/18723 | 6.73e-03 | 2.46e-02 | 140 |
GO:001095119 | Esophagus | ESCC | negative regulation of endopeptidase activity | 135/8552 | 252/18723 | 6.86e-03 | 2.51e-02 | 135 |
GO:005254720 | Oral cavity | OSCC | regulation of peptidase activity | 255/7305 | 461/18723 | 5.78e-13 | 2.75e-11 | 255 |
GO:005254820 | Oral cavity | OSCC | regulation of endopeptidase activity | 235/7305 | 432/18723 | 4.35e-11 | 1.40e-09 | 235 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
A2ML1 | SNV | Missense_Mutation | novel | c.1624A>G | p.Ser542Gly | p.S542G | A8K2U0 | protein_coding | tolerated(0.55) | benign(0.042) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
A2ML1 | SNV | Missense_Mutation | c.3011N>T | p.Gly1004Val | p.G1004V | A8K2U0 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-AA-3982-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
A2ML1 | SNV | Missense_Mutation | novel | c.699N>C | p.Gln233His | p.Q233H | A8K2U0 | protein_coding | deleterious(0.01) | possibly_damaging(0.726) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
A2ML1 | SNV | Missense_Mutation | rs368024371 | c.1438G>A | p.Asp480Asn | p.D480N | A8K2U0 | protein_coding | deleterious(0.02) | possibly_damaging(0.864) | TCGA-AA-3994-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
A2ML1 | SNV | Missense_Mutation | novel | c.3458N>T | p.Arg1153Ile | p.R1153I | A8K2U0 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
A2ML1 | SNV | Missense_Mutation | c.4034N>A | p.Arg1345Gln | p.R1345Q | A8K2U0 | protein_coding | tolerated(0.08) | benign(0.018) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
A2ML1 | SNV | Missense_Mutation | c.4034N>A | p.Arg1345Gln | p.R1345Q | A8K2U0 | protein_coding | tolerated(0.08) | benign(0.018) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
A2ML1 | SNV | Missense_Mutation | rs749075339 | c.2414C>T | p.Ser805Phe | p.S805F | A8K2U0 | protein_coding | deleterious(0) | possibly_damaging(0.463) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
A2ML1 | SNV | Missense_Mutation | c.2769G>T | p.Lys923Asn | p.K923N | A8K2U0 | protein_coding | tolerated(0.81) | benign(0) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
A2ML1 | SNV | Missense_Mutation | novel | c.1140N>G | p.Ile380Met | p.I380M | A8K2U0 | protein_coding | deleterious(0) | possibly_damaging(0.519) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |